| Literature DB >> 25136978 |
Abstract
Catestatin (CST) was first discovered as a potent non-competitive and reversible inhibitor of catecholamine secretion. Recent reports on plasma CST level in heart diseases suggested a cardioprotective role for this peptide. Given that cardiac remodeling is the dominant pathologic process in cardiac dysfunction, we propose that CST participates in the regulation of concern pathways and contributes to the inhibition of cardiac remodeling. In this minireview, the potential mechanism of cardiac remodeling involving CST will be discussed from three aspects: hypertrophy, fibrosis, and apoptosis.Entities:
Keywords: Apoptosis; cardiac remodeling; catestatin; fibrosis; hypertrophy
Mesh:
Substances:
Year: 2014 PMID: 25136978 DOI: 10.3109/1354750X.2014.950331
Source DB: PubMed Journal: Biomarkers ISSN: 1354-750X Impact factor: 2.658